Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 17/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863010 | 1.00 | REN (0.53) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1863007 | 1.00 | REN (0.53) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1863953 | 1.00 | REN (0.53) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1859108 | 0.96 | REN (0.58) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1866114 | 0.96 | REN (0.58) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1859111 | 0.96 | REN (0.58) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1866111 | 0.96 | REN (0.58) | RENMEN1KMT2ATAAR1ALDH1A1 | |
| SCHEMBL1863288 | 0.89 | REN (0.59) | REN | |
| SCHEMBL1863291 | 0.89 | REN (0.59) | REN | |
| SCHEMBL1868456 | 0.89 | REN (0.59) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | REN 298/4885MEN1 2596/4885KMT2A 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.